Baxter International Inc (BAX) 35.40 $BAX
Baxter International (BAX) Q3 Earnings: Surprise in Store?
Zacks Equity Research - Zacks Investment Research - Fri Oct 23, 12:47PM CDT
Baxter's expanding product portfolio, benefits from the Baxalta spin-off and cost synergies from the Gambro acquisition are expected to be major tailwinds.
BAX: 35.40 (+0.48), AMAG: 37.85 (+4.24), ICLR: 68.33 (+0.74), AFFX: 9.09 (+0.09)
PetMed (PETS) Q2 Earnings Beat, Revenues Meet Estimates
Zacks Equity Research - Zacks Investment Research - Fri Oct 23, 11:00AM CDT
PetMed Express, Inc. (PETS), announced earnings per share (EPS) of 22 cents in the second quarter of fiscal 2016.
PETS: 16.71 (+0.09), BAX: 35.40 (+0.48), NUVA: 47.18 (+1.83), HRC: 51.73 (+0.97)
ResMed (RMD) Misses Q1 Earnings Hit by Currency Woes
Zacks Equity Research - Zacks Investment Research - Fri Oct 23, 8:40AM CDT
ResMed (RMD) reported a mixed first-quarter fiscal 2016 with revenues beating the Zacks Consensus Estimate and earnings missing the same
BAX: 35.40 (+0.48), RMD: 56.25 (+0.75), NUVA: 47.18 (+1.83), HRC: 51.73 (+0.97)
Baxter to Present at the Credit Suisse Healthcare Conference
Business Wire - Thu Oct 22, 3:15PM CDT
Baxter International Inc. (NYSE: BAX) announced today that it will present at the Credit Suisse Healthcare Conference on Wednesday, November 11, 2015 at 11:30 a.m. (CT).
BAX: 35.40 (+0.48)
Varian (VAR) Announces Preliminary Fiscal 2015 Results
Zacks Equity Research - Zacks Investment Research - Thu Oct 22, 11:40AM CDT
Varian Medical Systems, Inc. (VAR) expects adjusted EPS for the fiscal to be lower than its previous guidance.
MASI: 38.45 (+0.09), VAR: 77.26 (+1.36), BAX: 35.40 (+0.48), NUVA: 47.18 (+1.83)
Global Medical Specialty Bags Market Report 2015-2019 - Key Vendors are B Braun Medical, Coloplast, Hollister, Pall & Terumo
M2 - Thu Oct 22, 10:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jslhrn/global_medical) has announced the addition of the "Global Medical Specialty Bags Market: Research Report 2015-2019" report to their offering. The global medical speciality bags market to grow at a CAGR of 5.22% over the period 2014-2019. The report, Global Medical Speciality Bags Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers North America, Europe, APAC, and ROW; it also covers the global medical speciality bags market landscape and its growth prospects in the coming years. The report also includes a discussion on the key vendors operating in this market. Increased use of disposable bags is a leading trend in the global medical speciality bags market. With the increase in cases of infection and the risk of cross contamination, there has been a sudden increase in the demand for disposable bags. People have become more aware about the various health issues caused by reusing bags like urine bags or enema bags. According to the report, the increase in the prevalence of chronic diseases drives the growth of the global medical speciality bags market. The rising number of chronic diseases such as cancer, cardiovascular diseases, and kidney diseases has increased the demand for medical speciality bags. Further, the report states that the rise in the number of counterfeit healthcare products is a major challenge for this market. People are ready to pay extra for bag packages containing anti-counterfeit tags. In addition, the low awareness about diseases and their treatment is a significant challenge that hinders the growth of the market. Key vendors - B Braun Medical - Coloplast - Hollister - Pall - Terumo Other prominent vendors - AdvacarePharma - Baxter International - CR Bard - Convatec - Fresenius Medical Care - Innvol - Kawasumi Laboratories - Kingsystems - KNF Flexpak - Lily Medical - Mediplus - Pennine Healthcare - Phoenix Medical Systems Key Topics Covered: Part 01: Executive summary Part 02: Scope of the report Part 03: Market research methodology Part 04: Introduction Part 05: Market landscape Part 06: Market segmentation by type of bags Part 07: Geographical segmentation Part 08: Market drivers Part 09: Impact of drivers Part 10: Market challenges Part 11: Impact of drivers and challenges Part 12: Market trends Part 13: Vendor landscape Part 14: Key vendor analysis Part 15: Appendix For more information visit http://www.researchandmarkets.com/research/js...al_medical
BAX: 35.40 (+0.48)
Global Hemophilia A Market 2015-2019
M2 - Thu Oct 22, 9:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kmq3vn/global_hemophilia) has announced the addition of the "Global Hemophilia A Market 2015-2019" report to their offering. The global hemophilia A drugs market to grow at a CAGR of 6.25% over the period 2014-2019. The report, Global Hemophilia A Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers APAC, Europe, and Americas; it also covers the landscape of the global hemophilia A drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. The report covers the current scenario and the growth prospects of the global hemophilia A drugs market for the period of 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment and prevention of hemophilia A. In this report, the market is also segmented based on the type of therapy. There are new technological advancements in terms of drug manufacturing, development, and delivery. These advances has led to the development of recombinant products. For instance, animal or human plasma proteins are not used to manufacture NovoSeven, thereby decreasing the risk of infection. The use of Fc-fusion technology has increased the half-life of Eloctate in blood, thereby improving drug action. According to the report, the development of new hemophilia A therapeutics with prolonged action is prompting market growth. Vendors are developing a number of products, which are in the pipeline stage. The anticipated approval of these products will impact the growth of the market during the forecast period. Further, the report states that the high cost of treatment leads to the discontinuation of therapy, thereby hampering market growth. Key vendors - Baxter International - Bayer's - CSL Behring - Novo Nordisk - Pfizer Other prominent vendors - Alnylam Pharmaceuticals - Amarna Therapeutics - Asklepios - Biogen Idec - Catalyst Biosciences - Dimension Therapeutics - Dong-A Socio - Emergent BioSolutions - Grifols - Inspiration Biopharmaceuticals - Kedrion Biopharma - Octapharma - OPKO Health - rEVO Biologics - Sangamo BioSciences - Spark Therapeutics - UniQure For more information visit http://www.researchandmarkets.com/research/km...hemophilia
BIIB: 276.99 (+0.16), NVO: 55.72 (+2.07), EBS: 30.14 (+0.08), OPK: 9.45 (+0.42), ONCE: 61.81 (+2.85), BAX: 35.40 (+0.48), SGMO: 7.19 (+0.76), CBIO: 4.27 (-0.13), RBIO: (), DMTX: 12.25 (+1.45)
Baxter names Michael F. Mahoney to board
M2 - Thu Oct 22, 3:29AM CDT
Hospital products company Baxter International (NYSE:BAX) revealed on Wednesday the addition of Michael F. Mahoney to its
Baxter International (BAX) Q3 Earnings: Surprise in Store?
Zacks Equity Research - Zacks Investment Research - Fri Oct 23, 12:47PM CDT
Baxter's expanding product portfolio, benefits from the Baxalta spin-off and cost synergies from the Gambro acquisition are expected to be major tailwinds.
BAX: 35.40 (+0.48), AMAG: 37.85 (+4.24), ICLR: 68.33 (+0.74), AFFX: 9.09 (+0.09)
PetMed (PETS) Q2 Earnings Beat, Revenues Meet Estimates
Zacks Equity Research - Zacks Investment Research - Fri Oct 23, 11:00AM CDT
PetMed Express, Inc. (PETS), announced earnings per share (EPS) of 22 cents in the second quarter of fiscal 2016.
PETS: 16.71 (+0.09), BAX: 35.40 (+0.48), NUVA: 47.18 (+1.83), HRC: 51.73 (+0.97)
ResMed (RMD) Misses Q1 Earnings Hit by Currency Woes
Zacks Equity Research - Zacks Investment Research - Fri Oct 23, 8:40AM CDT
ResMed (RMD) reported a mixed first-quarter fiscal 2016 with revenues beating the Zacks Consensus Estimate and earnings missing the same
BAX: 35.40 (+0.48), RMD: 56.25 (+0.75), NUVA: 47.18 (+1.83), HRC: 51.73 (+0.97)
Baxter to Present at the Credit Suisse Healthcare Conference
Business Wire - Thu Oct 22, 3:15PM CDT
Baxter International Inc. (NYSE: BAX) announced today that it will present at the Credit Suisse Healthcare Conference on Wednesday, November 11, 2015 at 11:30 a.m. (CT).
BAX: 35.40 (+0.48)
Varian (VAR) Announces Preliminary Fiscal 2015 Results
Zacks Equity Research - Zacks Investment Research - Thu Oct 22, 11:40AM CDT
Varian Medical Systems, Inc. (VAR) expects adjusted EPS for the fiscal to be lower than its previous guidance.
MASI: 38.45 (+0.09), VAR: 77.26 (+1.36), BAX: 35.40 (+0.48), NUVA: 47.18 (+1.83)
Global Medical Specialty Bags Market Report 2015-2019 - Key Vendors are B Braun Medical, Coloplast, Hollister, Pall & Terumo
M2 - Thu Oct 22, 10:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jslhrn/global_medical) has announced the addition of the "Global Medical Specialty Bags Market: Research Report 2015-2019" report to their offering. The global medical speciality bags market to grow at a CAGR of 5.22% over the period 2014-2019. The report, Global Medical Speciality Bags Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers North America, Europe, APAC, and ROW; it also covers the global medical speciality bags market landscape and its growth prospects in the coming years. The report also includes a discussion on the key vendors operating in this market. Increased use of disposable bags is a leading trend in the global medical speciality bags market. With the increase in cases of infection and the risk of cross contamination, there has been a sudden increase in the demand for disposable bags. People have become more aware about the various health issues caused by reusing bags like urine bags or enema bags. According to the report, the increase in the prevalence of chronic diseases drives the growth of the global medical speciality bags market. The rising number of chronic diseases such as cancer, cardiovascular diseases, and kidney diseases has increased the demand for medical speciality bags. Further, the report states that the rise in the number of counterfeit healthcare products is a major challenge for this market. People are ready to pay extra for bag packages containing anti-counterfeit tags. In addition, the low awareness about diseases and their treatment is a significant challenge that hinders the growth of the market. Key vendors - B Braun Medical - Coloplast - Hollister - Pall - Terumo Other prominent vendors - AdvacarePharma - Baxter International - CR Bard - Convatec - Fresenius Medical Care - Innvol - Kawasumi Laboratories - Kingsystems - KNF Flexpak - Lily Medical - Mediplus - Pennine Healthcare - Phoenix Medical Systems Key Topics Covered: Part 01: Executive summary Part 02: Scope of the report Part 03: Market research methodology Part 04: Introduction Part 05: Market landscape Part 06: Market segmentation by type of bags Part 07: Geographical segmentation Part 08: Market drivers Part 09: Impact of drivers Part 10: Market challenges Part 11: Impact of drivers and challenges Part 12: Market trends Part 13: Vendor landscape Part 14: Key vendor analysis Part 15: Appendix For more information visit http://www.researchandmarkets.com/research/js...al_medical
BAX: 35.40 (+0.48)
Global Hemophilia A Market 2015-2019
M2 - Thu Oct 22, 9:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kmq3vn/global_hemophilia) has announced the addition of the "Global Hemophilia A Market 2015-2019" report to their offering. The global hemophilia A drugs market to grow at a CAGR of 6.25% over the period 2014-2019. The report, Global Hemophilia A Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers APAC, Europe, and Americas; it also covers the landscape of the global hemophilia A drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. The report covers the current scenario and the growth prospects of the global hemophilia A drugs market for the period of 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment and prevention of hemophilia A. In this report, the market is also segmented based on the type of therapy. There are new technological advancements in terms of drug manufacturing, development, and delivery. These advances has led to the development of recombinant products. For instance, animal or human plasma proteins are not used to manufacture NovoSeven, thereby decreasing the risk of infection. The use of Fc-fusion technology has increased the half-life of Eloctate in blood, thereby improving drug action. According to the report, the development of new hemophilia A therapeutics with prolonged action is prompting market growth. Vendors are developing a number of products, which are in the pipeline stage. The anticipated approval of these products will impact the growth of the market during the forecast period. Further, the report states that the high cost of treatment leads to the discontinuation of therapy, thereby hampering market growth. Key vendors - Baxter International - Bayer's - CSL Behring - Novo Nordisk - Pfizer Other prominent vendors - Alnylam Pharmaceuticals - Amarna Therapeutics - Asklepios - Biogen Idec - Catalyst Biosciences - Dimension Therapeutics - Dong-A Socio - Emergent BioSolutions - Grifols - Inspiration Biopharmaceuticals - Kedrion Biopharma - Octapharma - OPKO Health - rEVO Biologics - Sangamo BioSciences - Spark Therapeutics - UniQure For more information visit http://www.researchandmarkets.com/research/km...hemophilia
BIIB: 276.99 (+0.16), NVO: 55.72 (+2.07), EBS: 30.14 (+0.08), OPK: 9.45 (+0.42), ONCE: 61.81 (+2.85), BAX: 35.40 (+0.48), SGMO: 7.19 (+0.76), CBIO: 4.27 (-0.13), RBIO: (), DMTX: 12.25 (+1.45)
Baxter names Michael F. Mahoney to board
M2 - Thu Oct 22, 3:29AM CDT
Hospital products company Baxter International (NYSE:BAX) revealed on Wednesday the addition of Michael F. Mahoney to its
